In the last trading session, 1.71 million shares of the Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) were traded, and its beta was -0.47. Most recently the company’s share price was $3.01, and it changed around $0.01 or 0.33% from the last close, which brings the market valuation of the company to $257.93M. AMLX currently trades at a discount to its 52-week high of $19.42, offering almost -545.18% off that amount. The share price’s 52-week low was $1.58, which indicates that the current value has risen by an impressive 47.51% since then.
Amylyx Pharmaceuticals Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.00. If we narrow it down even further, the data shows that 0 out of 6 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 3 recommended AMLX as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight. Amylyx Pharmaceuticals Inc is expected to report earnings per share of -0.62 for the current quarter.
Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) trade information
Instantly AMLX has showed a green trend with a performance of 0.33% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 3.35 on recent trading dayincreased the stock’s daily price by 10.15%. The company’s shares are currently down -20.37% year-to-date, but still down -1.63% over the last five days. On the other hand, Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) is -17.53% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $9, which translates to bulls needing to increase their stock price by 66.56% from its current value. Analyst projections state that AMLX is forecast to be at a low of $4 and a high of $11.
Amylyx Pharmaceuticals Inc (AMLX) estimates and forecasts
The year-over-year growth rate is expected to be -100.00%, down from the previous year.
The company’s sales for the same quarters a year ago were 88.64M and -1.02M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -100.00%. Forecasts for the next quarter put sales growth at 100.00%.
Amylyx Pharmaceuticals Inc earnings are expected to increase by 56.09% in 2025, but the outlook is positive 38.11% per year for the next five years.
AMLX Dividends
Amylyx Pharmaceuticals Inc’s next quarterly earnings report is expected to be released in April.
AQR CAPITAL MANAGEMENT LLC, with 4.9114% or 3.34 million shares worth $6.35 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and abrdn Healthcare Investors were the top two Mutual Funds as of Sep 30, 2024 . The former held 1.81 shares worth $5.45 million, making up 2.64% of all outstanding shares. On the other hand, abrdn Healthcare Investors held roughly 1.37 shares worth around $4.12 million, which represents about 2.00% of the total shares outstanding.
